Willow Biosciences Inc.

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
0.09 ^CAD	0.00%		+5.88%	-10.00%

Apr. 01	Willow Biosciences Narrows 2023 Loss YOY	MT
Mar. 29	Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Willow Biosciences Inc. Appoints Barbara Munroe to its Board of Directors

May 07, 2021 at 04:55 pm EDT

Willow Biosciences Inc. announced that Ms. Barbara Munroe has been appointed to the Board of Directors of the company.

Latest news about Willow Biosciences Inc.

Willow Biosciences Narrows 2023 Loss YOY	Apr. 01	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	Mar. 01	MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient	Feb. 21	MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.	Feb. 19	CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	Jan. 31	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	Jan. 31	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	Jan. 31	CI
Willow Biosciences Announces Collaboration With Enterin	Jan. 16	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	Jan. 16	CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights	Jan. 10	MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024	Jan. 10	MT
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue	Dec. 07	DJ
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program	Dec. 07	MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program	Dec. 07	MT
Willow Biosciences Reports Q3 Results, Provides Update	Nov. 15	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Willow Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Aurora Cannabis Announcing Settlement of Patent Litigation	23-10-24	MT
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding	23-10-09	CI
Willow Biosciences and Suanfarma Detail Collaboration	23-10-03	MT
Willow Biosciences Inc. and Suanfarma Announce Collaboration on Development of Large Volume Anti-Infective API Through Precision Fermentation	23-10-03	CI
Willow Biosciences Announced Company Insider Led Convertible Debenture Financing	23-09-12	MT
Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding	23-09-11	CI
Willow Biosciences Announced Completion of R&D Program on Cost Effective, Sustainably Produced UDCA	23-09-06	MT

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
WILLOW BIOSCIENCES INC.	-10.00%	8.37M
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals